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Highlights 
 The intravenous and intramuscular administration of MEL in lactating goats showed a similar 
pharmacokinetic profile. 
 The IM bioavailability was complete 
 In silico simulation showed plasma concentration above the therapeutic plasma concentrations 
determined for other animal species  
 MEL depletion in milk shown to be in line with that reported for cattle. 
 
Abstract 
Domestic goats, although present in large numbers worldwide, are still considered a minor species in 
Europe and the USA. Due to their minor status, new therapies directed to relieve pain is a neglected 
area of investigation. Unfortunately there is a lack of approved drugs for this species and many drugs 
are administered in an extra-label manner. Often no information on the safety profile for goats and 
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for humans consuming their products is available. Meloxicam (MEL) is a potent anti-inflammatory 
drug characterized by a preferential COX-2 isoenzyme inhibition. The aim of this study was to 
determine the pharmacokinetics of MEL at the dose of 0.5 mg/kg in lactating goats after intravenous 
(IV) and intramuscular (IM) administration and to quantify its residues in milk. The analytical method 
was performed by the HPLC diode array detector. The IV and IM administrations of MEL in lactating 
goats showed suitable pharmacokinetic profiles for this animal species. The IM route showed a 
bioavailability of 105% and long half-life of elimination (10.82 hr). The simulation of multiple daily 
IM injections provides a plasma concentration above the therapeutic concentrations determined for 
other species for the majority of 24 hr. The high IM bioavailability, the long half-life of elimination 
and the mean plasma concentration at the steady state suggested that once a day administration might 
be sufficient. MEL residues were quantifiable in milk up to 48 hr in IM group and 60 hr in IV group. 
These data seems to be in line with the milk depletion reported in cattle. Further studies are necessary 
to establish if the minimal effective concentration determined in other animal species can be applied 
to goats too. 
 
Keywords: meloxicam, lactating goats, pharmacokinetics, intravenous and intramuscular injection, 
milk residue. 
  
AC
CE
PT
ED
 M
AN
US
CR
IPT
Introduction 
Production of animal food derivatives safe for the human consumption is one of the most important 
issues of this century (Zylberman, 2004). On the other hand, society has become progressively more 
conscious about potential suffering in production animals and aware of the necessity of new pain 
therapies for its prevention and treatment (Giorgi et al., 2016). Therefore, there is a demand for novel 
therapies to relieve pain in food producing animals (De Vito, 2015). 
Nowadays, though domestic goats are present as a worldwide population in numbers large enough to 
confer a status of major species, these animals are still considered as a minor species by the regulatory 
agencies in Europe and the USA (Toutain et al., 2010). Due to the lower number of goats compared 
to the other livestock species their health issues cannot be addressed with EMA or FDA-approved 
medications. Consequently, many drugs are administered to goats in an extra-label manner with no 
scientific information on drug behaviour, potential toxicity, and adequate withdrawal periods for drug 
removal from products marketed for human consumption (Clothier, 2010). 
Meloxicam (MEL) is a potent anti-inflammatory drug having analgesic and antipyretic properties. 
MEL, has been shown to be preferential in inhibiting COX-2 (12 times more selective as a COX-2 
inhibitor in the dog) than COX-1 isoenzyme (Kay et al., 2000).  
The pharmacokinetic profile of MEL shows good absorption, longer elimination half-life and high 
extravascular bioavailability in different animal species: dogs (Hare et al., 2013; Montoya et al., 
2004; Busch et al., 1998), cats (Lehr et al., 2010; Giraudel et al., 2005), horses (Lees et al., 1991; 
Toutain and Cester, 2004; Toutain et al., 2004; Burns et al., 2010), rabbits (Turner et al., 2006; 
Carpenter et al., 2009), turtles (Di Salvo et al., 2016), green iguanas (Divers et al., 2010), piglets 
(Alassane et al., 2010; Fosse and Spadavecchia, 2011), cattle (Johnn et al., 2011; Coetzee et al., 2009, 
2012; Mosher et al., 2012), camels (Wasfi et al., 2012) and Ilamas (Amanda et al., 2012). Little and 
conflicting information only is available for small ruminants (Shukla et al., 2007; Ingvast-Larssom 
et al., 2011; Wani et al., 2013; Wani et al., 2014). 
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The aim of the present study was two-fold: i) to determine the pharmacokinetics of MEL after 
intravenous (IV) and intramuscular (IM) route of administrations at the dose of 0.5 mg/kg b.w. in 
goats; ii) to quantify MEL residues in milk.  
 
Materials and methods 
Chemicals and reagents 
The pure powder (purity >99.8%) of MEL was provided by LCG Promochem (Milan, Italy). The 
pure powder of piroxicam, the internal standard (IS), (> 99.8%) was provided by LCG Promochem 
(Milan, Italy). Acetonitrile (ACN), sodium chloride (NaCl), potassium dihydrogen phosphate 
(KH2PO4) and phosphoric acid (H3PO4) were used in the assays (Scharlau, Milan, Italy). All the other 
reagents and materials were provided from commercial sources. 
Animals and experimental design 
The animal experiment was approved by the animal welfare ethics committee of the University of 
Lublin (authorization 43/2017) and carried out in accordance with the European law (2010/63/UE). 
Six healthy 1-2 year old mixed breed lactating goats, with an average weight of 55 (±4) kg were used 
in the study. Goats were examined to be clinically healthy based on blood analysis (CBC and serum 
biochemistry profile) and absence of any apparent clinical signs before the commencement of the 
study. All the animals were housed in an animal shed and were acclimatized to the new environment 
for 7 days. The animals were fed twice a day and water was provide ad libitum. The feed was withheld 
the night preceding the day of the experiment until 6 hr post drug administration. 
Goats were randomly assigned to 2 treatment groups (6 slips of paper marked with the numbers from 
1 to 6 in a box), using an open, single-dose, two-treatment, two-phase, unpaired, cross-over design 
(2x2 Latin square). On the day of experiment, the goats’ necks were shaved and a local anaesthetic 
(Emla®, ointment, lidocaine 25 mg⁄g, prilocaine 25 mg⁄g; AstraZeneca) was spread on the skin above 
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the jugular veins. Two catheters were placed in the jugular veins, one in the left jugular for blood 
sampling in both the groups and a second one, only for the IV group, in the right jugular for drug 
administration. Group A (n=3) received a single dose of MEL (Metacam® solution for injection 20 
mg/mL, Boehringer Ingelheim) at 0.5 mg/kg b.w. intravenously. Group B (n=3) received the same 
dose of MEL by an intramuscular injection in to the right gluteal muscle. A wash-out period of 3 
weeks was observed between phases, the groups were rotated and the experiment was repeated. Blood 
samples (10 mL) were collected immediately before and at 5, 15, 30 and 45 min, 1, 1.5, 2, 4, 6, 8, 10, 
24, 36, 48, 60, 72, 96, 120, 144, and 168 hr after administration of the drug in heparinised tubes. 
Goats were totally milked from both udders immediately before and after the administration of the 
drug at 10, 24, 36, 48, 60, 72, 96, 120, 144, and 168 hr. After centrifugation at 4500xg for 10 min 
blood, plasma was harvested and samples (plasma and milk) were stored at -20 °C until use within 
30 days from collection. A licensed veterinarian (BLW) evaluated the presence of likely adverse 
effects from the time of drug administration up to 7 days. Physical exam, changes in behaviour, food 
intake, heart rate and temperature were monitored and the injection site regularly examined for signs 
of inflammation. 
High-Performance Liquid Chromatography 
The HPLC method was based on a previously published technique (Kimble et al., 2013) with slight 
modifications. The chromatographic separation assay was performed with a Gemini C18 analytical 
column (250 x 4.6 mm inner diameter, 5-μm particle size, Phenomenex) maintained at 25° C. The 
mobile phase consisted of ACN (A): 0.05 M phosphate buffer pH 3.2 (B) at an isocratic flow rate of 
1 mL/min. The wavelength was set at 365 nm. The analytical method was re-validated for lactating 
goats’ plasma and milk samples according to the EMA guidelines (2012) by examining the within-
run precision calculated from similar responses for six repeats of 3 control samples (0.05, 0.5, and 1 
μg/mL) in one run. The between-run precision was determined by comparing the calculated response 
of the low (0.05 μg/mL), middle (0.50 μg/mL), and high (1 μg/mL) control samples over three 
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consecutive daily runs (total of 6 runs). The assay accuracy for within-run and between-runs was 
established by determining the ratio of calculated response to expected response for low (0.05 
μg/mL), middle (0.5 μg/mL), and high (1 μg/mL) control samples over 6 runs. Limit of quantitation 
(LOQ) was determined as signal-to-noise ratios of 10, and the limit of detection (LOD) as the signal-
to-noise ratios of 3.  
Quantification 
MEL and IS singular stock solutions in ACN were prepared at the concentration of 1000 μg/mL, were 
diluted to reach a final concentration of 100 μg/mL and stored at -20 °C. MEL solution was diluted 
in glass tubes (10 mL) to reach final concentrations of 5, 2.5 and 1 μg/mL and were stored at 4° C. 
These last concentrations were then diluted to prepare a 7-point calibration curve at the following 
concentrations 2.5, 1, 0.5, 0.1, 0.05, 0.025 and 0.015 µg/mL of MEL in plasma and milk matrices. 
Standard curves were constructed with standard MEL concentrations vs ratio of MEL/internal 
standard peak areas. The analyte was stable for at least 20 weeks if stored at 4° C. Linearity of the 
regression curve for plasma and milk were assessed on the basis of the residual plot, the fit test and 
the back calculation. The efficiency of extraction method was evaluated by comparing the response 
(in area) of high, middle, low standards and the IS, spiked into blank plasma or milk, to the response 
of equivalent standards. 
Preparation of plasma and milk samples  
In a 15 mL polypropylene snap cap tube containing 500 µL of plasma, a volume of 100 μL of IS 
solution (10 μg/mL) was added. After vortexing, 2.2 mL of ACN was added to the samples and 
vortexed again. Finally, 0.1 gr of NaCl was added for the optimal separation of the organic and 
aqueous phases. After vortexing, samples were shaken for 10 min at 60 osc/min and then centrifuged 
for 10 min at 4500 g and the organic layer (2 mL) was transferred into a clean 5 mL polypropylene 
snap cap conical tube. The organic phase was evaporated under a gentle stream of nitrogen at 40 °C 
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and reconstituted with 200 µL of the mobile phase. Fifty µL of this latter solution was injected onto 
the HPLC system equipped with diode array detector. 
Milk samples (500 µL each sample) were added to 100 μL of IS solution (10 μg/mL). After vortexing, 
2.2 mL of ACN was added to the samples and vortexed again. Finally 0.1 gr of NaCl was added to 
optimize the separation of the organic and aqueous phases. After vortexing, samples were shaken for 
10 min at 60 osc/min and then centrifuged for 10 min at 4500 g and the organic layer (2 mL) was 
transferred into a clean 5 mL polypropylene snap cap conical tube. The organic phase was evaporated 
under a gentle stream of nitrogen at 40 °C and reconstituted with 200 µL of the mobile phase. Fifty 
µL of this latter solution was injected onto the HPLC system equipped with diode array detector. 
Pharmacokinetic analysis 
MEL plasma concentration vs time curves were modelled for each subject using compartmental 
analysis (Gibaldi and Perrier, 1982). Comparison between competing models was made using the 
goodness of fit, Akaike’s information criterion, Schwarz Bayesian information criterion, the sum of 
square of the residuals and the visual inspection of the curves. The pharmacokinetic calculations were 
carried out using WinNonlin v 5.3.1 (Pharsight, La Lolla, CA, USA). The elimination half-life 
(Beta_HL) was evaluated by ln2/beta while the elimination rate constant (K10) was estimated by the 
formula alpha*beta/K21. The half-life in milk was calculated according to a non-compartment model. 
Area under the plasma vs time curve (AUC) was calculated from 0 to the last quantifiable 
concentration using a linear trapezoidal method. For intravenous administration, plasma clearance 
(Cl) and the total volume of distribution at steady-state (Vss) were determined. 
The IM bioavailability (F%) was calculated as: 
F= 
AUC (IM)
AUC (IV)
 𝑥 100 
Afterwards, basing on the pharmacokinetic data, a WinNonlin 5.3.1 simulation was performed. It was 
executed to establish if multiple administrations of MEL to goats IM at 0.5 mg/kg once a day would 
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achieve the values of average therapeutic plasma concentration (MEC) reported in literature for cats 
(347 ng/mL), dogs (833 ng/mL) and horses (735 ng/mL). These latter values were calculated from 
approved maintenance dose and reported clearance values (Toutain et al., 2004; Toutain and 
Lassourd, 2002). In agreement with the MEC values of MEL reported above, other PK/PD studies 
performed in cats and horses showed EC50 values of about 900 ng/mL and 195 ng/mL in horse and 
cat, respectively (Toutain and Cester, 2004; Giraudel et al., 2005). 
Statistical Analysis  
The Kolmogorov-Smirnov test was applied to verify data distribution. Statistical comparison of PK 
parameters was determined with Student’s t-test and performed by Graph Pad In Stat (Graph Pad 
Software). The PK parameters and MEL residues in milk are presented as means ± SD. In all 
experiments, differences were considered significant if p< 0.05. 
 
Results 
The HPLC method was revalidated using plasma and milk from control goats. Briefly, MEL 
concentration was linear in the range of 15–2500 ng/mL for both plasma and milk with correlation 
coefficients > 0.998. LOD was 5 ng/mL and LOQ was 15 ng/mL for both plasma and milk. When 
samples exceeded the upper limit of the range, they were re-analysed after appropriate dilution. The 
recoveries obtained were 89.3 ± 5.8% and 85.7 ± 3.2% for plasma and milk samples, respectively. 
The intra-day relative standard deviation for plasma and milk was lower than 4.6% and 5.1% 
respectively, whereas inter-day relative standard deviation was lower than 6.2% and 6.9%, 
respectively. 
No visible adverse effects (changes in behaviour, appetite, heart rate, temperature and signs of 
inflammation at the injection site) were observed during the experiment.  
Pharmacokinetics of meloxicam 
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Following IV and IM administrations of MEL at the dose of 0.5 mg/kg b.w, the plasma concentration 
vs time curves are illustrated in Figure 1. MEL plasma concentrations after IV and IM administrations 
were detectable up to 96 hr. At 120 hr, the drug concentrations dropped below the LOQ of the method. 
Pharmacokinetic parameters of MEL after IV injection were best fitted with the two-compartmental 
model, while a one-compartmental model best fitted plasma concentration after IM injection. MEL 
elimination phase from plasma was similar in both the administration groups. These similarities 
between routes of administration were proved by the pharmacokinetic parameters shown in Table 1 
and 2. No pharmacokinetic parameters were shown to be significantly different between routes of 
administration. The bioavailability (F%) after IM administration was 105.0 ± 8.23%. 
The plasma concentration vs time curve of the simulated multiple dose (0.5 mg/kg/day) of MEL by 
IM injection in goats is illustrated in figure 2. At the steady state, the AUC value was 32593 hr*ng/mL 
and the mean plasma concentration within 24 hr was 1358 ng/mL. 
Disposition of MEL in milk 
MEL concentrations following IV and IM injection at the dose of 0.5 mg/kg b.w. were quantifiable 
in the milk samples up to 60 and 48 hr, respectively (Figure 3). The average milk concentration 
showed similar trends between groups. The half-lives after both the administrations were not 
statistically different (9.6 ± 0.9 h, IV vs 9.3 ± 0.7h, IM) 
 
Discussion 
The primary objective of this study was to determine the pharmacokinetics of MEL in lactating goats 
after IV and IM administrations.  
After IV administration the bi-compartment model provided the best fit of the concentration-time 
data while after IM injection the best fit was provide by the mono-compartment model. This 
difference can be triggered by a common phenomenon and is due to the value of the absorption rate 
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constant being similar or lower than the rate constant for the distribution phase. In this study, the 
absorption phase did not appear in the curves and the drug’s disposition performed better with an 
open mono-compartment model (Gibaldi and Perrier, 1982).  
Some information about MEL pharmacokinetics in goats and other small ruminant species is present 
in the literature (Shukla et al., 2007; Ingvast-Larsson et al., 2011; Wani et al., 2013; Wani et al., 
2014). In the present study, the mean AUC value (26499 ± 4233 ng*hr/mL) was similar to data 
reported by Shukla et al., (2007) (19230 ± 2230 ng*hr/mL) and Ingvast-Larsson et al., (2011) (29738 
± 8576 ng*hr/mL) where goats received the same dose administered in the present study (0.5 mg/kg). 
In contrast, this value is in disagreement with data reported by Wani et al., (2013), if normalized for 
the dose (2635 ± µg*hr/mL at the dose of 1 mg/kg b.w.). The mean half-lives of elimination obtained 
in the present study (9.96 and 10.82 hr) were similar to the values reported by Ingvast-Larsson et al., 
(2011) (10.9 hr) but higher than those reported by Shukla et al., (2007) (7 hr) and Wani et al., (2013) 
(8 h). Finally, the mean values of Cl (19.38 ± 3.86 mL/hr/kg) and Vss (262.37  ± 50.74 mL/kg) 
obtained in the present study were in agreement with data reported by Ingvast-Larsson et al., (2011) 
(Cl 17.9 ± 4.3 mL/hr/kg and Vss 245 ± 62 mL/kg) and Wani et al., (2013) (Cl 22 mL/hr/kg and Vss 
276 mL/kg). In contrast, Shukla et al., (2007) reported a similar Vss value (250 mL/kg) but different 
plasma Cl (30 mL/hr/kg). These differences could be due to differences in weight (Shukla et al., 2007 
about 20 kg, Ingvast-Larsson et al., 2011 about 44 kg, present study about 55 kg), variations in breed 
used in the diverse studies, and to the different LOQ of the analytical techniques (Toutain and 
Bousquet-Mélou, 2004). 
Concerning the IM route of administration of MEL in goats, few data are reported in the literature. A 
study of Ingvast-Larssom et al., (2011) presented an estimated half life of elimination value of 14.4 
± 5.2 hr obtained in 3 hornless goat kids after IM administration of MEL. This value represents an 
estimation of half life of elimination only, due to the small number of animals used and the small 
number of blood samples collected in that study. A similar mean half life of elimination value (10.82 
± 2.75 hr) was shown in the present study.  
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A dosage regimen of 0.5 mg/kg b.w. once a day by IM administration was simulated. The steady state 
was achieved after the third administration. The plasma concentration values at the steady state 
simulated in the present study were always above the MEC for cats (347 ng/mL). In contrast, the 
plasma concentrations of MEL were above the MEC value reported in dog (833 ng/mL) for 16 out of 
the 24 hrs. It should be keep in mind though that the mean plasma concentration within 24 hr (1358 
ng/mL) obtained after the simulation was well above the MEC reported for dogs (833 ng/mL) or the 
EC50 in horse (900 ng/mL). However, further information is needed to determine the true MEC of 
meloxicam in goats.  
The F% in this study is > 100%. This value can be explained as experimental error occurring during 
the different phases of the study. However, several other studies in the literature report a similar 
phenomena (Lee et al., 2017; Giorgi et al., 2013). 
In conclusion, the relatively long half life of elimination, the complete F% of the IM injection and 
the high value of the mean plasma concentration within 24 hr calculated after simulation, suggests 
that the drug might be administered once a day by the IM route. 
Disposition of MEL in milk 
Few drugs are approved and labelled for lactating goats because of the likely drug residues in the 
milk. After a single dose of MEL by IV and IM administrations, the drug residues showed similar 
concentrations and a similar trend of elimination. This is in line with the similar trend of elimination 
reported for the plasma and the complete IM F%. Milk samples were collected in the present study 
until 168 h but MEL concentrations could only be quantified until 48h and 60h for IM and IV groups, 
respectively.  
No maximum residual limits established for lactating goats are allowed in milk entering in the human 
food chain. Concerning the approval for use of MEL in bovine, EMEA/MRL/635/99-FILAL (1999) 
identified MEL as the marker residue and the ratio to total residues of 0.75 for milk. Moreover, in 
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cattle, after a recommended single dose of 0.5 mg/kg b.w. administered by IV or subcutaneous 
injection, the corresponding mean concentrations of MEL for low and high milk yields were 347 and 
325 ng/mL, respectively. These values decline until the MRLs value (15 µg/kg) established for cattle 
is achieved at day 5 after the administration. Assuming the LOQ 15 ng/mL in the present study as a 
possible MRLs (Lin et al., 2016), after IV and IM injection milk concentrations fell below the LOQ 
at 72 and 60 hr, respectively. The rate of depletion in goat’s milk seems faster than that reported in 
cattle. These results could be due to the more active metabolism of goats compared with sheep or 
cattle (Toutain et al., 2010). This is linked to their respective feeding behaviour where goats are 
natural browsers that can stand on their hind legs or even climb trees. They preferably eat leaves, 
shrubs, flowers and fruits, thus choosing the most nutritious available food but also the portions of 
plants containing many toxic alkaloids that need to be metabolised by a hepatic first pass effect. In 
contrast cattle are a non-selective bulk feeder that graze non selective grass generally low in term of 
alkaloid content (Toutain et al., 2010). 
Further studies are needed however to determine the milk concentrations after multiple 
administrations of MEL at 0.5 mg/kg once a day in a larger number of animals to determine the 
accurate withdrawal time for milk intended for human consumption (EMEA/MRL/635/99-FILAL, 
1999; EMEA/CVMP/473/98-FINAL, 2000). 
 
Conclusion 
In conclusion, IV and IM administration of MEL in lactating goats showed similar pharmacokinetic 
profiles. The dose of 0.5 mg/kg used in the simulation study provided plasma concentrations above 
the MEC determined for other animal species for most of the 24 hr. This latter value along with the 
high IM F% and the long half-life of elimination suggested that the drug could be administered once 
a day. The present study showed that MEL concentrations in milk are to some extent in agreement 
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with the depletion of MEL in cattle milk. Further studies are required to clarify the dose needed to 
produce effective analgesia (MEC) and to avoid the risk of milk contamination in goats. 
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 Figure’ captions 
Figure 1. Mean plasma concentration vs time curve of MEL after IV (——) and IM (—●—) 
administrations at 0.5 mg/kg in lactating goats (n=6). Bars represent the SD. 
Figure 2. Mean plasma concentrations of MEL vs time curves following a simulated IM multiple 
dose rate at 0.5 mg/kg/day. The solid line (—) represents the MEC (833 ng/mL) of MEL in the dog; 
the square dotted line (….) represents the MEC (735 ng/mL) of MEL in the horse; the dash line (---) 
represents the MEC (347 ng/mL) of MEL in the cat (Toutain et al., 2004; Toutain and Lassourd, 
2002).  
Figure 3. Disposition of MEL in milk after IV (——) and IM (—●—) administration at the dose 
of 0.5 mg/kg b.w. in lactating goats (n=6). Bars represent the SD. 
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Table 
Table 1 
Pharmacokinetic parameters of MEL after IV administration at 0.5 mg/kg in lactating goats (n=6). 
                
     IV  
 
Parameter   Units   Mean   SD  
 AUC   hr*ng/mL   26499 ± 4233  
 K10   1/hr   0.12 ± 0.03  
 K12   1/hr   0.64 ± 0.38  
 K21   1/hr   1.13 ± 0.71  
 K10_HL   hr   6.07 ± 1.18  
 Alpha   1/hr   1.82 ± 1.09  
 Beta   1/hr   0.07 ± 0.02  
 Alpha_HL   hr   0.53 ± 0.35  
 Beta_HL   hr   9.96 ± 2.51  
 A   ng/mL   1223 ± 153.71  
 B   ng/mL   1840 ± 357.69  
 AUMC   hr*hr*ng/mL   374373 ± 120223  
 MRT   hr   13.88 ± 3.36  
 CL   mL/hr/kg   19.38 ± 3.86  
 Vss   mL/kg   262.37 ± 50.74  
 V1   mL/kg   165.76 ± 23.06  
 V2   mL/kg   96.61 ± 31.07  
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Area under the curve (AUC), elimination rate from compartment 1 (K10), rate of 
movement from compartment 1 to 2 (K12), the rate of movement from compartment 2 to 
1 (K21), half-life of the elimination phase (K10_HL), rate constant associated with 
distribution (), rate constant associated with elimination (), distribution half-life 
(Alpha _HL), elimination half-life (Beta_HL), intercept for the distribution phase (A), 
intercept for the elimination phase (B), area under the ﬁrst moment curve (AUMC), mean 
resident time (MRT); total clearance (CL), volume of distribution at the steady state 
(Vss), volume of compartment 1 (V1), and volume of compartment 2 (V2). 
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Table 2 
Pharmacokinetic parameters of MEL after IM administration at 0.5 mg/kg in lactating goats (n=6). 
                  
            IM     
  Parameter   Units   Mean   SD   
  Tmax   hr   3.73 ± 2.08   
  Cmax   ng/mL   1409 ± 40.78   
  AUC   hr*ng/mL   28071 ± 7630   
  K01   1/hr   1.13 ± 0.86   
  K10   1/hr   0.07 ± 0.01   
  K01_HL   hr   1.08 ± 0.76   
  K10_HL   hr   10.82 ± 2.75   
  CL/F   mL/hr/kg   18.77 ± 4.29   
  V/F   mL/kg   280.85 ± 33.50   
  F%       105.93 ± 8.23   
                  
 
 
 
Time to maximum plasma concentration (Tmax), maximum plasma concentration 
(Cmax), area under the curve (AUC), absorption rate (K01), elimination rate (K10), 
half-life of the absorption phase (K01_HL), half-life of the elimination phase (K10_HL), 
total body clearance per bioavailability (CL/F), apparent volume of distribution (V/F), 
and bioavailability (F%) 
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